Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:55:45 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CDTX - CIDARA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CDTX - Q3.00.679·0.78150.10.681-0.041-5.7361.12026310.705  0.74  0.681.48  0.59318:52:50Apr 0515 min RT 2¢

Recent Trades - Last 10 of 631
Time ETExPriceChangeVolume
18:52:50Q0.7015-0.02055
16:41:11Q0.68-0.04280
16:41:11Q0.68-0.04280
16:09:37Q0.685-0.0371,644
16:00:01Q0.681-0.041953
16:00:01Q0.681-0.041579
16:00:01Q0.681-0.041100
16:00:01Q0.681-0.0411,000
16:00:01Q0.681-0.041401
16:00:01Q0.681-0.04144

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-05 15:00U:CDTXNews ReleaseCidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
2024-03-06 08:00U:CDTXNews ReleaseCidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
2024-02-12 08:00U:CDTXNews ReleaseCidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
2024-01-29 16:30U:CDTXNews ReleaseCidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
2023-12-22 07:30U:CDTXNews ReleaseCidara Therapeutics Announces European Approval of REZZAYO ‚ ® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
2023-12-07 08:00U:CDTXNews ReleaseCidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
2023-12-06 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
2023-11-30 08:00U:CDTXNews ReleaseCidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
2023-11-20 08:00U:CDTXNews ReleaseCidara Therapeutics Named as a San Diego Metro Area Top Workplace
2023-11-03 12:00U:CDTXNews ReleaseCidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC ¢ € ™s 38 ¡ µ — Š ° Annual Meeting
2023-11-02 16:15U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
2023-10-13 10:34U:CDTXNews ReleaseCidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
2023-10-11 08:30U:CDTXNews ReleaseCidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
2023-09-29 16:52U:CDTXNews ReleaseCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-09-27 08:00U:CDTXNews ReleaseCidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
2023-09-07 08:00U:CDTXNews ReleaseCidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak ‚ ® Development Pipeline on September 21, 2023
2023-09-06 16:05U:CDTXNews ReleaseCidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
2023-09-06 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Janssen ¢ € ™s Election to Proceed Under its License Agreement Relating to Novel Drug-Fc Conjugates Targeting Influenza
2023-08-16 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development
2023-08-03 16:08U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results